# Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

> **NCT06723691** · PHASE1 · COMPLETED · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 57 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Acetaminophen
- **DRUG:** Metformin
- **DRUG:** Warfarin
- **DRUG:** Atorvastatin
- **DRUG:** Digoxin
- **DRUG:** HRS9531

## Key facts

- **NCT ID:** NCT06723691
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-18
- **Primary completion:** 2025-06-09
- **Final completion:** 2025-06-09
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06723691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06723691, "Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06723691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*